---
title: "Enhertu (fam-trastuzumab deruxtecan-nxki), all indications: Guidelines questions"
description: "Guidelines questions on Enhertu (fam-trastuzumab deruxtecan-nxki) that apply to every indication, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Questions: Which NCCN antiemetic regimens apply to highly emetogenic drugs such as Enhertu? 1 question quoted from 1 source."
canonical: "https://www.evicenter.com/medical-information/enhertu/guidelines"
published: "2026-11-14T01:54:55-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Enhertu (fam-trastuzumab deruxtecan-nxki), all indications: Guidelines questions

Manufacturer: Daiichi Sankyo, Inc.; AstraZeneca Pharmaceuticals LP  
Prescribing information: [Enhertu](https://daiichisankyo.us/prescribing-information-portlet/getPIContent?productName=Enhertu&inline=true)  
Indication pages: [HR-positive HER2-low or HER2-ultralow breast cancer](https://www.evicenter.com/medical-information/enhertu--hr-positive-her2-low-or-her2-ultralow-breast-cancer)

## Guidelines

<a id="enhertu-nccn-antiemetic"></a>

### Which NCCN antiemetic regimens apply to highly emetogenic drugs such as Enhertu?

> “The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines<sup>®</sup>) for Antiemesis recommends 3-4–drug prophylactic antiemetic regimens for high emetic risk agents to prevent both acute and delayed emesis during every cycle<sup>2,e,f</sup>”

Source: [ENHERTU: Select Adverse Reactions, captured 2026-11-13](https://www.enhertuhcp.com/en/managing-adverse-reactions/other-select-adverse-reactions#:~:text=The%20NCCN%20Clinical%20Practice%20Guidelines,and%20delayed%20emesis%20during%20every)

> “Consider option A, B, or C
> All treatments are NCCN Category 1 and should be started before anticancer therapy<sup>g</sup>”

Source: [ENHERTU: Select Adverse Reactions, captured 2026-11-13](https://www.enhertuhcp.com/en/managing-adverse-reactions/other-select-adverse-reactions#:~:text=Consider%20option%20A%2C%20B%2C%20or,should%20be%20started%20before%20anticancer)

> “Day 1	Day 2	Day 3	Day 4
> Option A
> Preferred	
> Olanzapine<sup>h</sup>
> NK1 RA
> 5-HT3 RA<sup>i,j</sup>
> Dexamethasone<sup>k,l</sup>
>
> Olanzapine<sup>h</sup>
> Oral aprepitant (if oral aprepitant used on Day 1)
> ±Dexamethasone<sup>k,l</sup>
>
> Olanzapine<sup>h</sup>
> Oral aprepitant (if oral aprepitant used on Day 1)
> ±Dexamethasone<sup>k,l</sup>
>
> Olanzapine<sup>h</sup>
>
> ±Dexamethasone<sup>k,l</sup>
>
> Option B<sup>m</sup>	
> Olanzapine<sup>h</sup>
> Palonosetron
> Dexamethasone<sup>k,l</sup>
>
> Olanzapine<sup>h</sup>
>
> Olanzapine<sup>h</sup>
>
> Olanzapine<sup>h</sup>
>
> Option C<sup>m</sup>	
> NK1 RA
> 5-HT3 RA<sup>i,j</sup>
> Dexamethasone<sup>k,l</sup>
>
> Oral aprepitant (if oral aprepitant used on Day 1)
> Dexamethasone<sup>k,l</sup>
>
> Oral aprepitant (if oral aprepitant used on Day 1)
> Dexamethasone<sup>k,l</sup>
>
>
> Dexamethasone<sup>k,l</sup>”

Source: [ENHERTU: Select Adverse Reactions, captured 2026-11-13](https://www.enhertuhcp.com/en/managing-adverse-reactions/other-select-adverse-reactions#:~:text=Day%201,Oral%20aprepitant%20%28if%20oral%20aprepitant%20used%20on%20Day%201%29)

> “The high emetic risk protocol includes management for 4 total days”

Source: [ENHERTU: Select Adverse Reactions, captured 2026-11-13](https://www.enhertuhcp.com/en/managing-adverse-reactions/other-select-adverse-reactions#:~:text=The%20high%20emetic%20risk%20protocol%20includes%20management%20for%204%20total%20days)

> “Antiemetic regimens should be chosen based on the drug with the highest emetic risk as well as patient-specific risk factors.”

Source: [ENHERTU: Select Adverse Reactions, captured 2026-11-13](https://www.enhertuhcp.com/en/managing-adverse-reactions/other-select-adverse-reactions#:~:text=Antiemetic%20regimens%20should%20be%20chosen,well%20as%20patient%2Dspecific%20risk%20factors.)

> “Adapted with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines<sup>®</sup>) for Antiemesis V.1.2026.”

Source: [ENHERTU: Select Adverse Reactions, captured 2026-11-13](https://www.enhertuhcp.com/en/managing-adverse-reactions/other-select-adverse-reactions#:~:text=Adapted%20with%20permission%20from%20the,for%20Antiemesis%20V.1.2026.)

Note: The NCCN recommendation applies to all high emetic risk anticancer agents; the Enhertu HCP site applies it because the product is classified as highly emetogenic. The table columns are Days 1 to 4; the letters after drug names are footnote markers on the source page. The site's reference list gives an access date of April 3, 2026, for the NCCN Guidelines for Antiemesis V.1.2026.

## Related pages
- [Medical information: Enhertu (fam-trastuzumab deruxtecan-nxki): All indications](https://www.evicenter.com/medical-information/enhertu)
- [Indication](https://www.evicenter.com/medical-information/enhertu/indication)
- [Pharmacology](https://www.evicenter.com/medical-information/enhertu/pharmacology)
- [Safety](https://www.evicenter.com/medical-information/enhertu/safety)
- [Specific populations](https://www.evicenter.com/medical-information/enhertu/specific-populations)
- [Drug interactions](https://www.evicenter.com/medical-information/enhertu/drug-interactions)
- [Dosing and administration](https://www.evicenter.com/medical-information/enhertu/dosing-and-administration)
- [Storage and supply](https://www.evicenter.com/medical-information/enhertu/storage-and-supply)
- [Access and coverage](https://www.evicenter.com/medical-information/enhertu/access-and-coverage)
